Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ProstaFluor** is an experimental diagnostic drug, specifically an antibody-photosensitizer conjugate designed for targeted detection and possibly therapy of prostate cancer. It acts by inhibiting both **KLK3 (Prostate-specific antigen, PSA)** and **PSMA (Prostate-specific membrane antigen)**, which are highly expressed in prostate cancer cells. The drug utilizes antibody targeting to bind selectively to these prostate cancer markers, and incorporates a fluorescent or photosensitizer moiety ("fluor"), making it suitable for use as a diagnostic dye in imaging or potentially for theranostic applications, such as image-guided surgery or targeted phototherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ProstaFluor.